Abstract:Ce Chen, 1, * Yingying Dong, 1, * Fei Liu, 2 Chengge Gao, 1 Cui Ji, 3 Yonghui Dang, 4 Xiancang Ma, 1 Yong Liu 5 1 Department of Psychiatry, First Affiliated Hospital of Medical College Xi'an Jiaotong University, Xi'an 710061, Shaanxi, People's Republic of China; 2 Clinical Research Center of Shaanxi Province for Dental and Maxillofacial Diseases, College of Stomatology, Xi'an Jiaotong University, Xi'an 710004, Shaanxi, People's Republic of China; 3 The Hospital of Xidian University, Xi'an 710071, Shaanxi, People's Republic of China; 4 College of Medicine & Forensics, Xi'an Jiaotong University Health Science Center, Xi'an 710061, Shaanxi, People's Republic of China; 5 The Institute of Neurobiology, Xi'an Jiaotong University, Xi'an 710061, Shaanxi, People's Republic of China *These authors contributed equally to this work Correspondence: Yong Liu The Institute of Neurobiology, Xi'an Jiaotong University, Yanta Road W. 76#, Xi'an, Shaanxi 710061, People's Republic of China Tel +8618189236156 Email liuy5599@mail.xjtu.edu.cn Aim: Post-stroke depression (PSD) is one of the most frequent neuropsychiatric disorders associated with stroke characterized by depression. The neuroplasticity hypothesis postulates that loss of brain-derived neurotrophic factor (BDNF) plays a major role in pathophysiology of PSD, and restoration of it may represent a critical mechanism underlying antidepressant efficacy. Methods: In previous studies, we designed a new fusion gene, HA2TAT-BDNF, and cloned it into adenovirus associated virus (AAV) to construct the BDNF-HA2TAT/AAV for the delivery of BDNF to central nervous system (CNS) via nose-brain pathway. In this study, we used it to explore the antidepressant effects on PSD rats through behavioral and various histological methods, and try to find out its specific mechanism. Results: Compared with the control group, the PSD+AAV group showed decreased sucrose consumption percentage in the sucrose preference test (SPT) (P 0.05, P > 0.05), showing an adequate antidepressant effect. Compared with the control group, the concentrations of BDNF mRNA and protein in the hippocampus (P< 0.05, P < 0.01) and prefrontal cortex (P < 0.01, P 0.05, P < 0.05), without notable change in the hippocampus (P < 0.05, P < 0.001) of PSD+BDNF rats. Conclusion: These results suggest that BDNF reductions in the prefrontal cortex and hippocampus are associated with the development of post-stroke depression, and that increased levels of BDNF in the prefrontal cortex could be used as a therapeutic target to treat PSD. However, the exact mechanism of BDNF action remains unclear in this regard, hindering the wider application of our method. We expect that our research could facilitate the exploration of pathogenesis and the new treatment method of PSD. Keywords: post-stroke depression, PSD, BDNF-HA2TAT/AAV, nasal-brain pathway, hippocampus, prefrontal cortex

Antidepressant-Like Action of Single Facial Injection of Botulinum Neurotoxin A is Associated with Augmented 5-HT Levels and BDNF/ERK/CREB Pathways in Mouse Brain

Neurocircuitry Underlying the Antidepressant Effect of Retrograde Facial Botulinum Toxin in Mice

The Behavioural Effects and Sept-Hippocampal Cholinergic Activity Changes Caused by Repeated Bont/A Injection on Facial Muscle in Adolescent Mice

Antidepressant-Like Action Of Single Facial Injection Of Botulinum Neurotoxin A Is Associated With Augmented 5-Ht Levels And Bdnf/Erk/Creb Pathways In Mouse Brain (Vol 35, Pg 661, 2019)

Unilateral Whisker Pad Injection of Botulinum Toxin Type a Enhances Spatial Learning in Mice.

Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective

Effects of Antidepressant on the Expression of Neuropeptide Y in Brain of a Rat Model of Depression Induced by Chronic Stress

Botulinum toxin A (BoNT/A) for the treatment of depression: A randomized, double-blind, placebo, controlled trial in China

The Safety and Efficacy of Botulinum Toxin A on the Treatment of Depression

A novel approach to treating post-stroke depression: administration of Botulinum Toxin A via local facial injection

Botulinum neurotoxin A ameliorates depressive-like behavior in a reserpine-induced Parkinson’s disease mouse model via suppressing hippocampal microglial engulfment and neuroinflammation

Intranasal Administration of Brain-Derived Neurotrophic Factor Rescues Depressive-Like Phenotypes in Chronic Unpredictable Mild Stress Mice

Andrographolide Exerts Significant Antidepressant-Like Effects Involving the Hippocampal BDNF System in Mice

The role of BDNF transcription in the antidepressant-like effects of 18β-glycyrrhetinic acid in a chronic social defeat stress model

Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine

Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: a Potential Promising Therapy Strategy for Major Depressive Disorder

Antidepressant effect of electroacupuncture regulates signal targeting in the brain and increases brain-derived neurotrophic factor levels

Antidepressant-Like Effects of GM1 Ganglioside Involving the BDNF Signaling Cascade in Mice

The effects of acupuncture on depression by regulating BDNF-related balance via lateral habenular nucleus BDNF/TrkB/CREB signaling pathway in rats

A Study of Antidepressant Effect and Mechanism on Intranasal Delivery of BDNF-HA2TAT/AAV to Rats with Post-Stroke Depression

Antidepressant Effects of TrkB Ligands on Depression-Like Behavior and Dendritic Changes in Mice after Inflammation.